Dr. Dan Sotirescu
Claim this profileEphrata Cancer Center
Studies Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
28 drugs studied
Area of expertise
1Cancer
HER2 positive
ER positive
ER negative
2Non-Small Cell Lung Cancer
Stage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Dan Sotirescu is currently running
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
More about Dan Sotirescu
Clinical Trial Related4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Dan Sotirescu has experience with
- Pembrolizumab
- Carboplatin
- Leucovorin Calcium
- Fluorouracil
- Irinotecan Hydrochloride
- Pemetrexed
Breakdown of trials Dan Sotirescu has run
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dan Sotirescu specialize in?
Dan Sotirescu focuses on Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Dan Sotirescu currently recruiting for clinical trials?
Yes, Dan Sotirescu is currently recruiting for 3 clinical trials in Ephrata Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Dan Sotirescu has studied deeply?
Yes, Dan Sotirescu has studied treatments such as Pembrolizumab, Carboplatin, Leucovorin Calcium.
What is the best way to schedule an appointment with Dan Sotirescu?
Apply for one of the trials that Dan Sotirescu is conducting.
What is the office address of Dan Sotirescu?
The office of Dan Sotirescu is located at: Ephrata Cancer Center, Ephrata, Pennsylvania 17522 United States. This is the address for their practice at the Ephrata Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.